📢 Check out this perspective review, highlighting the advancements brought by blood biomarkers in Alzheimer's disease🧠🩸 doi.org/10.1002/alz....

We were pleased to join an exciting symposium during #EANM25 last week in Barcelona focused on advancing early diagnosis with PET imaging and biomarkers. Lyduine Collij shared AMYPAD insights and spoke alongside Prof. Dr. Alexander Drzezga and Prof. dr. Silvia Morbelli. amypad.eu/news/recent-...

📢 NEW paper out in Alzheimer's & Dementia, using data from the AMYPAD Prognostic and Natural History Study! Congratulations to all authors 👏 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

🚀 We’re pleased to announce the release of the latest edition of our newsletter, featuring the release of the AMYPAD raw dataset, highlights from the Euro-PAD symposium and new papers! 👉 Read the full newsletter here: mailchi.mp/e602ab237ff7...

📣NEW AMYPAD out! The genetic data harmonisation manuscript for the AMYPAD consortium is online in Alzheimer's & Dementia! Authors provide a detailed pipeline for genotype array data QC, imputation, harmonisation, and PRS computation⤵️ doi.org/10.1002/alz....

📣 #AAIC25 is around the corner! Whether you’ll be on-site in Toronto or joining online, don’t miss the AMYPAD presentations 👇 For more information about the conference, please visit: aaic.alz.org

📢 NEW AMYPAD paper out in European Journal of Neurology assessing the cost-utility of early versus no amyloid-PET in the diagnostic work-up of memory clinic patients after 6 months. @ihieurope.bsky.social Congratulations to all authors 👏 doi.org/10.1111/ene....

This past two days, we hosted the Euro-PAD symposium to discuss the latest advancements in neuroimaging and biomarkers for #Alzheimer’s disease, as well as to share updates from the Euro-PAD initiative over the past year. ⤵️ www.barcelonabeta.org/en/news/news...

📣Yesterday and today, the Euro-PAD community convened in Barcelona for a scientific symposium hosted by @barcelonabeta.bsky.social. 👉Almost 100 participants gathered to discuss the latest advancements in neuroimaging and biomarkers for Alzheimer’s disease! amypad.eu/news/recent-...

This morning, before the symposium, we held two parallel workshops, one led by #BBRC researchers focused on fluid biomarkers and the other led by @acealzheimercenter.com focused on clinical trials

Today and tomorrow we are hosting the EuroPAD 2025 symposium! #EuroPAD seeks to enhance and extend late-stage biomarker cohorts focused on Alzheimer’s, with the specific aim of establishing the most extensive and deeply phenotyped longitudinal cohort of at-risk individuals.

📢 JUST PUBLISHED: Paper in @natrevdrugdiscov.nature.com on how to maximise #RegulatoryImpact from public-private partnerships, co-authored by IHI’s Nathalie Seigneuret. Check out 3 examples to follow from C-Path & @imi-amypad.bsky.social 👇 Read it below 👇 #IHITransformingHealth #RegulatoryScience

📣New paper out highlighting lessons learned that could help maximise the regulatory impact of consortium-based projects. C-Path and AMYPAD are featured as examples of projects that have achieved regulatory successes 👉https://www.nature.com/articles/d41573-025-00098-8

NEW paper out entitled "Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study" Congratulations to all authors 👏 Check it out now⤵️ link.springer.com/article/10.1...

📢Exciting news! We're pleased to announce that the AMYPAD raw dataset is now available for data access requests on the Alzheimer's Disease Data Initiative's Workbench! ➡️ Visit the AMYPAD website for more information: amypad.eu/data/

👉Leo Pieperhoff presented findings from the AMYPAD PHNS study at #ADPD2025 today! The harmonised data are available on the #ADWorkbench of the Alzheimer’s Disease Data Initiative. Interested to learn more? Visit Booth 16 of the Alzheimer’s Disease Data Initiative at #ADPD2025!

🧠 #ADPD2025 DAY 2! Join us in Room Hall F2 today at 13:50 for the symposium “WHITE MATTER ALTERATIONS”. Leonard Pieperhoff will be presenting AMYPAD results “Grey/White Matter Contrast Alterations Precede Amyloid Positivity and Atrophy Markers.” Don’t miss his insightful presentation 🙌

🚨#ADPD2025 is officially underway! This morning Mario Tranfa, Luigi Lorenzini and Emma Luckett presented data from the AMYPAD, EPAD and Euro-PAD consortiums! Natàlia Vilor Tejedor also presented the #ADWorkbench at the session hosted by the Alzheimer's Disease Data Initiative!

✨ Today marks the start of #ADPD2025 in Vienna! If you're attending the conference, don’t miss the AMYPAD, EPAD and EUROPAD-related talks. We hope to see you there to catch up on our latest advancements 🙌

👉 Earlier today, we were pleased to present insights from the AMYPAD project at #ECCN2025 during a satellite symposium, sponsored by Life Molecular Imaging! Thanks to everyone who joined us and contributed to the discussion ☺️

📣 Check out this new article providing a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of use. Congratulations to all authors 👏 doi.org/10.1002/alz....

🌟Good morning #ECCN25! Join us tomorrow for the AMYPAD satellite symposium "What does AMYPAD study reveal about centiloid relevance for the future clinical setting?" We're looking forward to seeing you!

If you are attending next week #ECCN25 in Madrid, don’t miss the AMYPAD satellite symposium on Tuesday, 25th March at 12:30. This session will explore the AMYPAD study's impact on centiloid relevance and its implications for future clinical practices.

✨The #ADPD2025 conference is just one month away in Vienna! AMYPAD, EPAD and EUROPAD will be presenting their latest insights in Alzheimer's disease research! We can't wait to see you there! 🙌

The 13th European Conference on Clinical Neuroimaging #ECCN25 will be held in Madrid next month! We're pleased to held a symposium exploring the AMYPAD study's impact on centiloid relevance & its implications for future clinical practices. We can’t wait to see you in Madrid!

📢 The latest edition of the AMYPAD newsletter was released last month! If you missed it, don't worry, catch up with the latest updates and ongoing efforts. The newsletter also includes new papers and an exclusive interview with Emma Luckett! Read the newsletter here ⤵️ https://buff.ly/40YvZGB

📢 Check out this recent opinion piece on the use of Centiloid threshold for anti-amyloid therapy published in The Journal of Prevention of Alzheimer's Disease. Many AMYPAD collaborators are acknowledged for sharing their input on the topic! doi.org/10.1016/j.tj...

👋 Hello Bluesky! We're a collaborative initiative aiming to improve the understanding, diagnosis & management of #Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. We continue to make significant strides despite being in the @ihieurope.bsky.social post-funding period⤵️ amypad.eu